Grant Number:	1R03CA119698-01 Interpret this number
Primary Investigator:	Holmes, Michelle
Organization:	Brigham And Women'S Hospital
Project Title:	Vitamin D Intake and Breast Cancer Survival
Fiscal Year:	2005

DESCRIPTION (provided by applicant): Multiple lines of evidence suggest that vitamin D intake may improve survival after a breast cancer diagnosis. Several human and animal studies have linked either dietary intake of vitamin D, vitamin D blood levels, or sun exposure with reduced risk of breast cancer incidence or breast cancer mortality. 1,25-Dihydroxyvitamin D (1,25(OH)2D), the biologically active form of vitamin D, can induce differentiation and apoptosis of transformed mammary cells. Vitamin D analogs are being explored as cancer therapeutic agents. In 1999, we reported a marginally significant reduced risk of death (378 deaths) among nearly 2000 participants with breast cancer, in the Nurses' Health Study (NHS), associated with higher vitamin D intake from food; to our knowledge, no other observational study has reported on vitamin D intake and survival after breast cancer. We propose to examine vitamin D intake and survival after a breast cancer diagnosis, in the NHS; we will expand on our previous report by utilizing 10 more years of follow-up, 5,000 more breast cancer survivors, and over 2000 deaths from breast cancer. In addition, we will also use a model for vitamin D status, developed in a subset of NHS participants with plasma 25-hydroxy vitamin D (25(OH)D) measurements, based on body mass index, region of inhabitance and physical activity as indicators for sunlight exposure, race as an indicator for skin pigmentation, and diet. We hypothesize that higher vitamin D intake and predicted vitamin D status after a breast cancer diagnosis are associated with a reduced risk of death from breast cancer. The vitamin D receptor (VDR) is a critical mediator of the cellular effects of vitamin D. A polymorphism in VDR (FOK1) has been shown to influence breast cancer risk. We hypothesize that women homozygous for this polymorphism will have an increased risk of death from breast cancer.





None